Eli Lilly and Company (LLY)
Eli Lilly (LLY) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Abbisko Cayman said on Wednesday that its Shanghai-based unit Abbisko Therapeutics has entered into a strategic research collaboration and license agreement with Eli Lilly.
Eli Lilly says Trump pricing policy will affect obesity drug launches in Europe
Eli Lilly expects to launch its weight-loss pill in Europe and Britain in the second half of 2026 or early 2027, with the drugmaker targeting the out-of-pocket telehealth market as it has done in the United States.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 Reasons to Buy Eli Lilly Stock
Eli Lilly still has a large addressable market in the anti-obesity space. The company boasts a deep pipeline of assets within and outside of its core therapeutic areas.
Prediction: Eli Lilly Will Trade at $1,200 on This Date
Eli Lilly (NYSE:LLY | LLY Price Prediction) just reported a quarter that should have sent bulls into a frenzy.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -1.19% move from the prior day.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day.
Here's Why Eli Lilly (LLY) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy
Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the
Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care
LLY wins FDA approval for every-8-week Ebglyss maintenance dosing in eczema, reducing injections per year while maintaining long-term disease control.
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Eli Lilly has solidified its leading position in the booming market for obesity drugs ahead of a wave of possible new entrants to the space.
